The Project

• The idea

  We developed an innovative nanotechnology-based point-of-care blood testing platform for the diagnosis of infectious diseases from a single drop of blood within a matter of minutes.

• Inspiration

  We felt the need for better, faster, and more efficient diagnostics for life-threatening diseases. During their PhD research, all founders contributed to different projects in this field. We are driven by the vision of turning research into products that improve the lives of people and reduce the impact of diseases.

• Unique selling points

  Patients can immediately receive results when visiting the doctor, allowing faster treatment and limiting the spread of diseases. The diagnostics platform is easy to use and does not require any trained personnel. The supporting technology is versatile enough to detect virtually any disease. The accuracy of our test is equal to standard laboratory equipment.

• Societal impact

  Our technology improves patient care and reduces workload in hospitals. Aside from COVID-19, our technology helps to mitigate the effects of mosquito-borne diseases, such as dengue fever. We contribute to the good health and well-being sustainability goal that aims to end neglected tropical diseases by 2030.

• Venture development

  Currently, BluSense is raising a round C of investment, which will provide financing to scale-up manufacturing, develop new products, go-to-market, and commercialisation.

• EIT Community support

  We received funding and we expect that the knowledge and network of EIT Manufacturing will significantly contribute to setting up and improving our manufacturing capabilities.